WeLeader Biomedical Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2022	FY 2021
Period Ending	Sep '23 Sep 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	150.66	153.8	105.77
Depreciation & Amortization	106.09	109.82	114.44
Loss (Gain) From Sale of Assets	2.33	-0.69	-0.41
Loss (Gain) From Sale of Investments	0.2	0.68	-0.01
Stock-Based Compensation	0.65	4.23	3.65
Provision & Write-off of Bad Debts	-0.55	-0.53	0.39
Other Operating Activities	-19.11	8.41	12.49
Change in Accounts Receivable	-7.2	21.59	-47.61
Change in Inventory	-8.08	-7.1	-13.37
Change in Accounts Payable	3	-5.37	43.39
Change in Unearned Revenue	-0.19	-1.25	1.02
Change in Other Net Operating Assets	8.3	-3.3	18.27
Operating Cash Flow	235.4	280.27	238.03
Operating Cash Flow Growth	-1.10%	17.75%	-
Capital Expenditures	-282.35	-659.36	-21.6
Sale of Property, Plant & Equipment	0.14	1.06	0.42
Sale (Purchase) of Intangibles	-1.47	-2.29	-2.3
Investment in Securities	10.67	-4.68	20.77
Investing Cash Flow	-273.01	-665.28	-2.71
Short-Term Debt Issued	-	247	53
Long-Term Debt Issued	-	291	20
Total Debt Issued	319.65	538	73
Short-Term Debt Repaid	-	-178.97	-122
Long-Term Debt Repaid	-	-118.66	-154.6
Total Debt Repaid	-378.76	-297.63	-276.6
Net Debt Issued (Repaid)	-59.11	240.37	-203.6
Issuance of Common Stock	111.48	143.64	-
Common Dividends Paid	-34.64	-9.77	-22.36
Other Financing Activities	-	-0.02	-
Financing Cash Flow	17.73	374.22	-225.96
Net Cash Flow	-19.88	-10.79	9.35
Free Cash Flow	-46.95	-379.09	216.43
Free Cash Flow Margin	-4.92%	-36.60%	25.73%
Free Cash Flow Per Share	-1.26	-12.46	7.70
Cash Interest Paid	11.19	6.42	6.31
Cash Income Tax Paid	54.02	28.44	11.83
Levered Free Cash Flow	-	-412.67	-
Unlevered Free Cash Flow	-	-410.04	-
Change in Net Working Capital	-	-15.92	-

Source: S&P Capital IQ. Standard template. Financial Sources.